Genvoya Clinical Trial Results
Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) has undergone several clinical trials to establish its efficacy and safety for treating HIV-1 infection. Key findings from these trials demonstrate its non-inferiority to other antiretroviral regimens and highlight its favorable safety profile, particularly concerning bone and kidney health compared to older tenofovir formulations.
How effective is Genvoya at suppressing HIV?
Genvoya has shown high rates of viral load suppression in clinical trials. In the Phase 3 GOLDER and LIRA studies, Genvoya demonstrated non-inferiority to comparator regimens in maintaining HIV-1 RNA levels below 50 copies/mL at 48 weeks [1]. These studies involved a diverse population of treatment-naïve individuals and those switching from stable suppressed regimens [1].
What are the long-term safety outcomes for Genvoya?
Long-term safety data indicate that Genvoya is generally well-tolerated. Compared to regimens containing tenofovir disoproxil fumarate (TDF), Genvoya, which contains tenofovir alafenamide (TAF), has shown a lower impact on bone mineral density and kidney function in clinical studies [1][2]. This is attributed to TAF's more targeted delivery to lymphoid cells, resulting in lower plasma concentrations of tenofovir [2].
How does Genvoya compare to other HIV medications?
Genvoya is a complete, single-tablet regimen (STR) designed for daily use. Its efficacy and safety have been evaluated against various established antiretroviral therapies. Studies have shown Genvoya to be non-inferior to regimens containing protease inhibitors or integrase strand transfer inhibitors (INSTIs) [1]. The advantage of Genvoya often lies in its integrated formulation and the improved renal and bone safety profile associated with TAF [2].
When did Genvoya receive FDA approval?
Genvoya was approved by the U.S. Food and Drug Administration (FDA) on November 5, 2015 [3]. This approval was based on data from the pivotal Phase 3 clinical trials, GOLDER and LIRA [1].
Are there any specific patient populations where Genvoya is recommended?
Genvoya is indicated for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older and weighing at least 35 kg (77 lb) who have no known mutations in the HIV-1 integrase gene and no prior treatment for HIV-1 infection [4]. It is also approved for patients who are switching from another complete regimen of HIV-1 antiretroviral medication because they meet criteria for certain drug interactions [4].
What are the potential side effects associated with Genvoya?
The most common side effects observed in clinical trials for Genvoya include nausea, diarrhea, and headache [4]. However, serious adverse events such as liver enzyme elevations and immune reconstitution inflammatory syndrome have also been reported [4]. The improved bone and kidney safety profile compared to TDF is a notable consideration for long-term use [2].